Mast Cells in Renal Cancer: Clinical Morphological Correlations and Prognosis

Черданцева, Т. М.; Бобров, И. П.; Avdalyan, A. M.; Климачев, В. В.; Казарцев, А В; Kryuchkova, N.G.; Климачев, И В; Myadelets, M N; Лепилов, А.В.; Лушникова, Е. Л.; Молодых, О. П.

doi:10.1007/s10517-017-3907-7

Cited by 20 publications

(11 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MCD had a correlation with the tumor size and angiogenesis within peritumorous zone. [28] depending on the type of tumor, MCs can have an immunosuppressive role by releasing IL-10, histamine, and TNF-α. Additionally, MCs may suppress T cells and NK cells by releasing adenosine into the microenvironment [2].…”

Section: Breast Cancermentioning

confidence: 99%

Role of Mast Cells in Shaping the Tumor Microenvironment

Komi

Redegeld

2019

Clinic Rev Allerg Immunol

223

181

View full text Add to dashboard Cite

Early mast cell (MC) infiltration has been reported in a wide range of human and animal tumors particularly malignant melanoma and breast and colorectal cancer. The consequences of their presence in the tumor microenvironment (TME) or at their margins still remain unclear as it is associated with a good or poor prognosis based on the type and anatomical site of the tumor. Within the tumor, MC interactions occur with infiltrated immune cells, tumor cells, and extracellular matrix (ECM) through direct cell-tocell interactions or release of a broad range of mediators capable of remodeling the TME. MCs actively contribute to angiogenesis and induce neovascularization by releasing the classical proangiogenic factors including VEGF, FGF-2, PDGF, and IL-6, and nonclassical proangiogenic factors mainly proteases including tryptase and chymase. MCs support tumor invasiveness by releasing a broad range of matrix metalloproteinases (MMPs). MC presence within the tumor gained additional significance when it was assumed that controlling its activation by tyrosine kinase inhibitors (imatinib and masitinib) and tryptase inhibitors (gabexate and nafamostat mesylate) or controlling their interactions with other cell types may have therapeutic benefit.

show abstract

Section: Breast Cancermentioning

confidence: 99%

Role of Mast Cells in Shaping the Tumor Microenvironment

Komi

Redegeld

2019

Clinic Rev Allerg Immunol

223

181

View full text Add to dashboard Cite

show abstract

“…MCs possess both pro-tumor and anti-tumor mediators, are found in large numbers in and around many types of tumors, and studies have variously suggested MCs should be targets for inhibition/depletion or exploited as an anti-tumorigenic strategy ( 67 ). There are various studies that showed MCs have an anti-tumorigenic role in ovarian cancer ( 68 ), clear-cell renal cell carcinoma (ccRCC) ( 69 ), B cell lymphoma ( 70 ), skin cancer ( 71 , 72 ), renal cancer ( 73 ), oral squamous cell carcinoma (OSCC) ( 74 , 75 ), non-small-cell lung cancer (NSCLC) ( 76 , 77 ), intestine cancer ( 71 , 78 ), lung cancer ( 79 ), melanoma ( 80 – 82 ), prostate cancer ( 83 – 85 ), colorectal cancer ( 86 ), and breast cancer ( 57 , 87 – 92 ) ( Figure 1A ). Patients with elevated MC counts had a significantly better event-free survival (EFS) compared to those with fewer MCs in several tumor types.…”

Section: In Cancer; Evidence For Both Anti- and Pro-tumor Rolesmentioning

confidence: 99%

Harnessing the Anti-Tumor Mediators in Mast Cells as a New Strategy for Adoptive Cell Transfer for Cancer

et al. 2022

View full text Add to dashboard Cite

The emergence of cancer immunotherapies utilizing adoptive cell transfer (ACT) continues to be one of the most promising strategies for cancer treatment. Mast cells (MCs) which occur throughout vascularized tissues, are most commonly associated with Type I hypersensitivity, bind immunoglobin E (IgE) with high affinity, produce anti-cancer mediators such as tumor necrosis factor alpha (TNF-α) and granulocyte macrophage colony-stimulating factor (GM-CSF), and generally populate the tumor microenvironments. Yet, the role of MCs in cancer pathologies remains controversial with evidence for both anti-tumor and pro-tumor effects. Here, we review the studies examining the role of MCs in multiple forms of cancer, provide an alternative, MC-based hypothesis underlying the mechanism of therapeutic tumor IgE efficacy in clinical trials, and propose a novel strategy for using tumor-targeted, IgE-sensitized MCs as a platform for developing new cellular cancer immunotherapies. This autologous MC cancer immunotherapy could have several advantages over current cell-based cancer immunotherapies and provide new mechanistic strategies for cancer therapeutics alone or in combination with current approaches.

show abstract

“…Since Cluster ( CD 8 < CD 4 ≈ M Φ) has the highest amount of mast cells compared to the other clusters, angiogenesis inhibitors might be a good treatment option for the patients in this cluster. Moreover, mast cells are suggested as an independent prognostic factor in some studies of ccRCC patients 43, 44 , and the amount of mast cells negatively correlated with 5-year survival 44 . However, our finding shows that the number of mast cells inversely correlated with the grade of tumors (Figure 3A, D), and the primary tumors of patients without tumors at the last time of follow up have higher percentages of mast cells than primary tumors of patients with tumor at the last time of follow up.…”

Section: Discussionmentioning

confidence: 99%

Immune Classification of Clear Cell Renal Cell Carcinoma

Akbarinejad

Shahriyari

2020

Preprint

View full text Add to dashboard Cite

ABSTRACTSince the outcome of treatments, particularly immunotherapeutic interventions, depends on the tumor immune micro-environment (TIM), several experimental and computational tools such as flow cytometry, immunohistochemistry, and digital cytometry have been developed and utilized to classify TIM variations. In this project, we identify immune pattern of clear cell renal cell carcinomas (ccRCC) by estimating the percentage of each immune cell type in 526 renal tumors using the new powerful technique of digital cytometry. The results, which are in agreement with the results of a large-scale mass cytometry analysis, show that the most frequent immune cell types in ccRCC tumors are CD8+ T-cells, macrophages, and CD4+ T-cells. Saliently, unsupervised clustering of ccRCC primary tumors based on their relative number of immune cells indicates the existence of four distinct groups of ccRCC tumors. Tumors in the first group consist of approximately the same numbers of CD8+ T-cells, CD4+ T-cells, and macrophages, while tumors in the second group have a significantly high number of macrophages compared to any other immune cell type (P-value< 0.01). The third group of ccRCC tumors have a significantly higher number of CD8+ T-cells than any other immune cell type (P-value< 0.01), while tumors in the group 4 have approximately the same numbers of macrophages and CD4+ T-cells and a significantly smaller number of CD8+ T-cells than CD4+ T-cells (P-value< 0.01). Moreover, there is a high positive correlation between the expression levels of IFNG and PDCD1 and the percentage of CD8+ T-cells, and higher stage and grade of tumors have a substantially higher percentage of CD8+ T-cells. Furthermore, the primary tumors of patients, who are tumor free at the last time of follow up, have a significantly higher percentage of mast cells (P-value< 0.01) compared to the patients with tumors for all groups of tumors except group 3.

show abstract

Mast Cells in Renal Cancer: Clinical Morphological Correlations and Prognosis

Cited by 20 publications

References 8 publications

Role of Mast Cells in Shaping the Tumor Microenvironment

Role of Mast Cells in Shaping the Tumor Microenvironment

Harnessing the Anti-Tumor Mediators in Mast Cells as a New Strategy for Adoptive Cell Transfer for Cancer

Immune Classification of Clear Cell Renal Cell Carcinoma

Contact Info

Product

Resources

About